Hemostemix Inc., of Calgary, Alberta, said it has concluded a first closing of the $1 million nonbrokered private placement of convertible debentures, and issued debentures in the amount of $525,000. The net proceeds will be used to continue to fund the company's phase II trial for critical limb ischemia and for general working capital.